AMAG PHARMACEUTICALS, INC. (NASDAQ:AMAG) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
attached hereto shall not be deemed filed for purposes of Section
18 of the Securities Exchange Act of 1934, as amended, (the
Exchange Act) or otherwise subject to the liabilities of that
section, nor shall they be deemed incorporated by reference in
any filing under the Securities Act of 1933, as amended, (the
Securities Act) except as expressly set forth by specific
reference in such filing.
release entitled AMAG Pharmaceuticals Announces First Quarter
2017 Financial Results regarding its operating results for the
quarter ended March 31, 2017 and its intention to hold a
conference call to discuss AMAGs financial and operating results
and recent developments. A copy of AMAGs press release is
furnished herewith as Exhibit 99.1 and a copy of the presentation
slides to be used during the conference call is furnished
herewith as Exhibit 99.2.
not be deemed filed for purposes of Section 18 of the Exchange
Act or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by reference in any filing under
the Securities Act, except as expressly set forth by specific
reference in such filing.
Announces Positive Topline Data From Phase 3 Feraheme
(ferumoxytol) Label Expansion Study” regarding a clinical trial
evaluating Feraheme. A copy of the press release is furnished
herewith as Exhibit 99.3.
|
Exhibit
Number
|
Description
|
|
|
99.1
|
Press release entitled AMAG Pharmaceuticals Announces
First Quarter 2017 Financial Results issued by AMAG Pharmaceuticals, Inc. on May 2, 2017. |
|
|
99.2
|
Copy of AMAG Pharmaceuticals, Inc.s presentation slides
dated May 2, 2017. |
|
|
99.3
|
Press release entitled AMAG Announces Positive Topline
Data From Phase 3 Feraheme (ferumoxytol) Label Expansion Study issued by AMAG Pharmaceuticals, Inc. on May 2, 2017. |
About AMAG PHARMACEUTICALS, INC. (NASDAQ:AMAG)
AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth. AMAG PHARMACEUTICALS, INC. (NASDAQ:AMAG) Recent Trading Information
AMAG PHARMACEUTICALS, INC. (NASDAQ:AMAG) closed its last trading session up +0.25 at 24.65 with 654,522 shares trading hands.